New drug duo targets Tough-to-Treat breast cancer
Disease control
Ongoing
This study is testing whether two existing oral drugs, ribociclib and bicalutamide, work better together to control advanced triple-negative breast cancer that has spread. The trial involves about 37 people whose cancer has a specific marker (the androgen receptor). The main goal…
Phase: PHASE1, PHASE2 • Sponsor: Kari Wisinski • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC